公开(公告)号：US20130237906A1

公开(公告)日：2013-09-12

申请号：US13880421

申请日：2011-10-19

申请人： Se-Ik Park ,  Jin-Woo Chang ,  Sung June Kim ,  Sung Eun Lee ,  Seung Woo Lee ,  Shin Ae Kim ,  Kyou Sik Min ,  Hyo Woon Moon ,  Hyung-Cheul Shin ,  Jin Won Kim

发明人： Se-Ik Park ,  Jin-Woo Chang ,  Sung June Kim ,  Sung Eun Lee ,  Seung Woo Lee ,  Shin Ae Kim ,  Kyou Sik Min ,  Hyo Woon Moon ,  Hyung-Cheul Shin ,  Jin Won Kim

IPC分类号： A61N1/05 ,  A61N5/06

CPC分类号： A61B5/04001 ,  A61B1/0017 ,  A61B5/6868 ,  A61N1/0551 ,  A61N1/36025 ,  A61N5/0601 ,  A61N5/0622 ,  A61N2005/0612 ,  Y10T156/1052

摘要： The invention relates to an electro-optrode neural interface, comprising an optical fiber which is elongated so as to be insertable into a body, and which is located at a core portion so as to form an optical electrode portion, and a liquid crystal polymer(LCP) sample encircling the optical fiber. The LCP sample has an adhesive sheet, and an LCP electrode layer encircling the adhesive sheet, wherein the adhesive sheet and the LCP electrode layer are coupled to each other. The electro-optrode neural interface is formed by combining into a single unit, an electrical interface in which an electrode for stimulating deep brain or measuring neural signals from deep brain is arranged in a liquid crystal polymet and an optical interface such as an optical fiber, a waveguide and an endoscope. The electro-optrode interface of the present invention may enable an electro-optrode to be inserted into a body which electrically or optically monitoring the position of the electro-optrode in real time, and may be mass producted.

摘要翻译： 电光神经接口技术领域本发明涉及一种电光神经接口，其特征在于，包括光纤，该光纤是细长的，以便被插入到主体中，并且位于芯部以便形成光电极部分，以及液晶聚合物 LCP）样品环绕光纤。 LCP样品具有粘合片和环绕粘合片的LCP电极层，其中粘合片和LCP电极层彼此连接。 电光神经界面是通过组合成单个单元，其中用于刺激深脑的电极或测量来自深脑的神经信号的电接口被布置在液晶聚合物和诸如光纤的光学界面中的电接口， 波导和内窥镜。 本发明的电光学界面可以使电光被插入到电或光学上实时监测电光位置的主体中，并且可以大规模生产。

公开(公告)号：US09096571B2

公开(公告)日：2015-08-04

申请号：US13696400

申请日：2011-05-04

申请人： Je Ho Ryu ,  Shin Ae Kim ,  Keun Ho Ryu ,  Jae Sun Kim ,  Nam Ho Kim ,  Hye Young Han ,  Yong Hyuk Kim ,  Won-No Youn ,  Yoon-Jung Lee ,  Hyun Joo Son ,  Bong-Yong Lee ,  Sung Hoon Park ,  Ju Young Lee ,  Hyun Jung Lee ,  Hoe Chul Jung ,  Young Ah Shin ,  Jung A Lee ,  Bo Ram Lee ,  Joon Ho Sa

发明人： Je Ho Ryu ,  Shin Ae Kim ,  Keun Ho Ryu ,  Jae Sun Kim ,  Nam Ho Kim ,  Hye Young Han ,  Yong Hyuk Kim ,  Won-No Youn ,  Yoon-Jung Lee ,  Hyun Joo Son ,  Bong-Yong Lee ,  Sung Hoon Park ,  Ju Young Lee ,  Hyun Jung Lee ,  Hoe Chul Jung ,  Young Ah Shin ,  Jung A Lee ,  Bo Ram Lee ,  Joon Ho Sa

IPC分类号： A61K31/47 ,  A61K31/55 ,  A61K31/445 ,  A61K31/497 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D213/81 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D239/557

CPC分类号： C07D401/04 ,  C07D213/81 ,  C07D239/557 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14

摘要： Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

摘要翻译： 提供了吡啶酰胺和嘧啶-4-甲酰胺化合物，其制备方法，含有该组合物的药物组合物，以及使用该化合物作为预防，调节和治疗与糖皮质激素调节有关的疾病的药物的用途 该化合物对于11-bgr-HSD1酶的选择性抑制活性。 本发明的吡啶酰胺和嘧啶-4-甲酰胺化合物是人源性11β-HSD1酶的选择性抑制剂，可用于预防，调节和治疗糖皮质激素调节相关疾病的药剂，其中人源性11β- ; -HSD1酶涉及例如代谢综合征，如1型和2型糖尿病，糖尿病后期并发症，潜伏性自身免疫性糖尿病成人（LADA），胰岛素耐受综合征，肥胖，葡萄糖耐量异常（IGT），空腹血糖受损 （IFG），葡萄糖耐量受损，血脂异常，动脉粥样硬化，高血压等。

公开(公告)号：US20130210811A1

公开(公告)日：2013-08-15

申请号：US13696400

申请日：2011-05-04

申请人： Je Ho Ryu ,  Shin Ae Kim ,  Keun Ho Ryu ,  Jae Sun Kim ,  Nam Ho Kim ,  Hye Young Han ,  Yong Hyuk Kim ,  Won-No Youn ,  Yoon-Jung Lee ,  Hyun Joo Son ,  Bong-Yong Lee ,  Sung Hoon Park ,  Ju Young Lee ,  Hyun Jung Lee ,  Hoe Chul Jung ,  Young Ah Shin ,  Jung A Lee ,  Bo Ram Lee ,  Joon Ho Sa

发明人： Je Ho Ryu ,  Shin Ae Kim ,  Keun Ho Ryu ,  Jae Sun Kim ,  Nam Ho Kim ,  Hye Young Han ,  Yong Hyuk Kim ,  Won-No Youn ,  Yoon-Jung Lee ,  Hyun Joo Son ,  Bong-Yong Lee ,  Sung Hoon Park ,  Ju Young Lee ,  Hyun Jung Lee ,  Hoe Chul Jung ,  Young Ah Shin ,  Jung A Lee ,  Bo Ram Lee ,  Joon Ho Sa

IPC分类号： C07D401/04 ,  C07D403/14 ,  C07D403/04 ,  C07D401/14 ,  C07D405/14

CPC分类号： C07D401/04 ,  C07D213/81 ,  C07D239/557 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14

摘要： Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

摘要翻译： 提供了吡啶酰胺和嘧啶-4-甲酰胺化合物，其制备方法，含有该组合物的药物组合物，以及使用该化合物作为预防，调节和治疗与糖皮质激素调节有关的疾病的药物的用途 化合物对11beta-HSD1酶的选择性抑制活性。 本发明的吡啶酰胺和嘧啶-4-甲酰胺化合物是人源性11beta-HSD1酶的选择性抑制剂，可用于预防，调节和治疗与糖皮质激素调节相关的疾病的药剂，其中人源性11β- 涉及HSD1酶，例如代谢综合征，如1型和2型糖尿病，糖尿病后期并发症，潜伏性自身免疫性糖尿病成年（LADA），胰岛素耐受综合征，肥胖症，葡萄糖耐量异常（IGT），空腹血糖受损（IFG ），葡萄糖耐量受损，血脂异常，动脉粥样硬化，高血压等。